Radiopharmaceuticals: Resolving an Enigma
Healthcare Unfiltered
00:00
Dose of Tumors and Toxicity
Right now we give flat dosing in general for these things, just like we would laima writes on some weight based dosing or a surface ara rate. And the issue there is that if a patient is the same sort of size, but they have significantly more tumor burden, they may not have enough os that we give an einoth activity. So i think those thoe, those nu ances need to be ironed out. I think this has enormous potential, because you don't even have to look for mutin target. It's a lot like cemotherapy. Now, we give it cause we give it, and if it works, it works. And
Transcript
Play full episode
